
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
Los Angeles - Among 3-year-olds, children with atopic dermatitis have significantly more melanocytic nevi than their unaffected counterparts, and the difference in nevi count overall can be accounted for by higher numbers of nevi present in light-skinned children with eczema, Robert Dellavalle, M.D., Ph.D., said at the annual meeting of the Society for Investigative Dermatology.